Dr. Ibrahim is recognized nationally as an expert in the field of Hematopathology and Molecular Pathology. Dr. Ibrahim previously held several positions at NYU School of Medicine and Hospitals (2001-2017), including Adjunct Professor, Director of Hematopathology/Molecular Pathology and Director of the Hematopathology Fellowship Program. He also served as a Hematopathology Consultant at Memorial Sloan-Kettering Cancer Center from 2008 to 2017.
He performed his Hematopathology Fellowship at the M D Anderson Cancer Center. Dr. Ibrahim contributed to the scientific literature in the field of Hematology and Oncology more than 60 peer-reviewed articles and several book chapters and presentations in Hematopathology and Molecular Pathology Dr. Ibrahim is routinely engaged by other pathologists and physicians to render second opinions on the most difficult to diagnose leukemia and lymphoma cases.
During his time as Director of Molecular Pathology, Dr Ibrahim was one of the first adaptors of next generation sequencing technology. He saw clearly that NGS could bring new possibilities to cancer care and so with the desire to give all patients access to comprehensive genetic testing, Dr. Ibrahim launched a subsidiary lab, PsiGenex, which will provide the same high level service to women’s health and beyond.
Dr. Azim received her PhD from the Department of Cancer Studies and Molecular Medicine, University of Leicester, UK in the field of Molecular Profiling of Diffuse Large B-Cell Lymphoma. She did her residency training in Anatomic and Clinical Pathology at the University of South Alabama, 2015. She finished her training as a Hemtopathology fellow at the New York University (NYU) – Langone in 2016, followed by fellowship in Molecular Genetics Pathology at The University of Nebraska in 2017. She served as the Director of Molecular Diagnostics and Hematopathologist at NYU-Winthrop University Hospital from 2017-2019 until joining PsiGenex.
.jpeg)
Prior to joining PsiGenex, Dr. Sun was the Director of the Special Coagulation Department at BioReference Labs. She has spent much of her career on clinical genomics developing a number of robust and cost effective assays at Genpath/BioReference and Pathline Laboratories. She has provided broad technical and logistical oversight on projects in Molecular Oncology, Reproductive Genetics and Infectious Disease by using multiple molecular technologies including Next Generation Sequencing (NGS) and microarray technologies. Dr. Sun received her PhD in Genetics and completed her fellowships at Rutgers University.Additionally, she has received Master degrees in Information Studies and Zoology. Dr. Sun has also authored numerous publications in scientific journals, as well as receiving 4 patents in the US. She has a certification of qualification as laboratory director in Molecular Oncology, Genetic Testing and Hematology from the New York State Department of Health.
Dr. Xiang previously held several positions at NexGenomics, HRC fertility (2015-2019), Ecahn School of Medcine at Mount Sinai (2015-2018), BayCare Medical Group (2014-2015), City of Hope Medical Center (2010-2013), University of Miami Medical center (2008-2010), Including Associate Professor, Director of Cytogenetics and Cytogenomics, Director of PGT-A. She has served as a Medical Genetics Consultant at BGI since 2017. Dr. Xiang is an ABMGG Board-Certified Cytogeneticist with over ten years’ experience in Cytogenetics of Oncology and Hematology and is a recognized expert in the field of arrayCGH clinical application on both Constitutional (Prenatal and Postnatal) and Cancer fields. She performed her Molecular Cytogenetics Fellowship at School of Medicine, Yale University. Dr. Xiang contributed to the scientific literature in the field of Molecular Cytogenetics more than 40 peer-reviewed articles and presentations; Dr. Xiang is also an Ad Hoc Reviewer for several Molecular Cytogenetics journals.
.jpg)
Dr. Gamal is a renowned subject matter expert in the field of precision medicine and molecular pathology. After receiving his medical degree and completing a residency in clinical pathology, Dr. Gamal decided to devote his long-life career to molecular pathology, focusing on the study, development, and implementation of advanced molecular diagnostic techniques. This stemmed from Dr. Gamal’s strong conviction that the future of medicine will be shaped mainly by molecular biomarker-based precision medicine.
Dr. Gamal has directly overseen the establishment of the Molecular divisions in several molecular diagnostics companies, from the ground up, and has been consulting for many others. He brings visionary leadership to the growing, highly promising field of companion diagnostics as it offers continuing advancements in diagnostic products and services that enable personalized medicine.
Among Dr. Gamal’s many achievements in that respect, is his leadership of the molecular department at Cancer Genetics Inc (CGI), where he spearheaded the development of numerous cutting edge molecular techniques and assays serving the pharmaceutical sector, while simultaneously overseeing the molecular oncology lab, which constitutes the diagnostic division of CGI. Following the acquisition of CGI by Interpace biosciences, Inc., Dr. Gamal led the foundation of a state-of-the-art molecular pathology laboratory at RTP, North Carolina.
Currently, Dr. Gamal is leading the Molecular department operations at PsiGenex
Filip Cacinovic is an experienced medical billing consultant and is responsible for all laboratory revenue streams. He was instrumental in the formation and development of the parent company, Cairo Diagnostics in 2013, where he still holds his position as the Director of Revenue Cycle. Filip brings a wide breadth of experience and knowledge of laboratory operations, income streams and risk mitigation. He has multiple publications in Nuclear Medicine across several major journals, most notably the European Journal of Nuclear Medicine. He holds a B.S. in Mathematics from Northeastern University with a focus on Risk Management.
.png){kind=logo}
At PsiGenex we believe that every patient should have access to comprehensive genetic testing. Specializing in advanced Next Generation Sequencing, our promise is to support patients through every stage of life. With our unwavering commitment to education, affordable testing, and reliable results, we aim to empower healthier lives through genetic testing.
Ask for us by name!
